Gantzer J, Toulmonde M, Severac F, Chamseddine AN, Charon-Barra C, Vinson C, Hervieu A, Bourgmayer A, Bertucci F, Ryckewaert T, Valentin T, Firmin N, Chaigneau L, Bompas E, Follana P, Rioux-Leclercq N, Soibinet-Oudot P, Bozec L, Le Loarer F, Weingertner N, Chevreau C, Duffaud F, Blay JY, Kurtz JE, Schöffski P, Brahmi M, Malouf GG

Cancer. 2024 03 12;:

Anticipating changes in the HER2 status of breast tumours with disease progression-towards better treatment decisions in the new era of HER2-low breast cancers.

Bergeron A, Bertaut A, Beltjens F, Charon-Barra C, Amet A, Jankowski C, Desmoulins I, Ladoire S, Arnould L

Br J Cancer. 2023 04 29;:

Prognostic factors and outcomes of adult spermatic cord sarcoma. A study from the French Sarcoma Group.

Achard G, Charon-Barra C, Carrere S, Bonvalot S, Meeus P, Fau M, Honoré C, Delhorme JB, Tzanis D, Le Loarer F, Karanian-Philippe M, Ngo C, Le Guellec S, Bertaut A, Causeret S, Isambert N

Eur J Surg Oncol. 2023 02 26;:

Real-World Experience of efficacy and safety of trabectedin in patients with soft tissue sarcoma: a bicentric retrospective analysis.

Chaigneau L, Jary M, Nerich V, Hervieu A, Aubry S, Charon Barra C, Meynard G, Neumann F, Kalbacher E, Isambert N

Oncology. 2022 10 25;:

Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.

Chevrier S, Brasselet A, Carnet M, Chevriaux A, Gibeaud A, Jourdain M, Mananet H, Truntzer C, Beltjens F, Charon-Barra C, Arnould L, Albuisson J, Comte A, Derangère V, Goussot V, Boidot R

Int J Mol Med. 2022 May;49(5):

Superficial CD34-Positive Fibroblastic Tumor and PRDM10-rearranged Soft Tissue tumor are overlapping entities: a comprehensive study of 20 cases.

Perret R, Michal M, Carr RA, Velasco V, Švajdler M, Karanian M, Meurgey A, Paindavoine S, Soubeyran I, Coindre JM, Boidot R, Charon-Barra C, Geneste D, Weingertner N, Pissaloux D, Tirode F, Baud J, Le Loarer F

Histopathology. 2021 Jun 14;:

Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-

Schöffski P, Toulmonde M, Estival A, Marquina G, Dudzisz-Śledź M, Brahmi M, Steeghs N, Karavasilis V, de Haan J, Wozniak A, Cousin S, Domènech M, Bovée JVMG, Charon-Barra C, Marreaud S, Litière S, De Meulemeester L, Olungu C, Gelderblom H

Eur J Cancer. 2021 May 29;152:26-40

Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations.

Bergeron A, MacGrogan G, Bertaut A, Ladoire S, Arveux P, Desmoulins I, Bonnefoi H, Loustalot C, Auriol S, Beltjens F, Degrolard-Courcet E, Charon-Barra C, Richard C, Boidot R, Arnould L

Mod Pathol. 2021 Mar 22;:

ER-/PR+ breast cancer: a distinct entity, which is morphologically and molecularly close to triple-negative breast cancer.

Beltjens F, Molly D, Bertaut A, Richard C, Desmoulins I, Loustalot C, Charon-Barra C, Courcet E, Bergeron A, Ladoire S, Jankowski C, Boidot R, Arnould L

Int J Cancer. 2021 Feb 26;:

Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network.

de Pinieux G, Karanian M, Le Loarer F, Le Guellec S, Chabaud S, Terrier P, Bouvier C, Batistella M, Neuville A, Robin YM, Emile JF, Moreau A, Larousserie F, Leroux A, Stock N, Lae M, Collin F, Weinbreck N, Aubert S, Mishellany F, Charon-Barra C, Croce S, Doucet L, Quintin-Rouet I, Chateau MC, Bazille C, Valo I, Chetaille B, Ortonne N, Brouchet A, Rochaix P, Demuret A, Ghnassia JP, Mescam L, Macagno N, Birtwisle-Peyrottes I, Delfour C, Angot E, Pommepuy I, Ranchere D, Chemin-Airiau C, Jean-Denis M, Fayet Y, Courrèges JB, Mesli N, Berchoud J, Toulmonde M, Italiano A, Le Cesne A, Penel N, Ducimetiere F, Gouin F, Coindre JM, Blay JY,

PLoS One. 2021 ;16(2):e0246958

Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer.

Boustani J, Derangère V, Bertaut A, Adotevi O, Morgand V, Charon-Barra C, Ghiringhelli F, Mirjolet C

Cells. 2020 Sep 10;9(9):

An exceptional metaplastic lobular breast carcinoma diagnosed through exome sequencing.

Bergeron A, Desmoulins I, Beltjens F, Causeret S, Charon-Barra C, Martin E, Richard C, Boidot R, Arnould L

J. Clin. Pathol.. 2020 Jan 24;:

Monitoring HSP70 exosomes in cancer patients' follow up: a clinical prospective pilot study.

Chanteloup G, Cordonnier M, Isambert N, Bertaut A, Hervieu A, Hennequin A, Luu M, Zanetta S, Coudert B, Bengrine L, Desmoulins I, Favier L, Lagrange A, Pages PB, Gutierrez I, Lherminier J, Avoscan L, Jankowski C, Rébé C, Chevriaux A, Padeano MM, Coutant C, Ladoire S, Causeret S, Arnould L, Charon-Barra C, Cottet V, Blanc J, Binquet C, Bardou M, Garrido C, Gobbo J

J Extracell Vesicles. 2020 ;9(1):1766192

Genomic and transcriptomic comparison of post-radiation versus sporadic sarcomas.

Lesluyes T, Baud J, Pérot G, Charon-Barra C, You A, Valo I, Bazille C, Mishellany F, Leroux A, Renard-Oldrini S, Terrier P, Le Cesne A, Laé M, Piperno-Neumann S, Bonvalot S, Neuville A, Collin F, Maingon P, Coindre JM, Chibon F

Mod. Pathol.. 2019 Jun 26;:

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.

Guiu S, Mollevi C, Charon-Barra C, Boissière F, Crapez E, Chartron E, Lamy PJ, Gutowski M, Bourgier C, Romieu G, Simony-Lafontaine J, Jacot W

Br. J. Cancer. 2018 07;119(1):76-79

Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC study.

Mirjolet C, Charon-Barra C, Ladoire S, Arbez-Gindre F, Bertaut A, Ghiringhelli F, Leroux A, Peiffert D, Borg C, Bosset JF, Créhange G

Oncoimmunology. 2018 ;7(3):e1396402

Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.

Jankowski C, Guiu S, Cortet M, Charon-Barra C, Desmoulins I, Lorgis V, Arnould L, Fumoleau P, Coudert B, Rouzier R, Coutant C, Reyal F

Breast Cancer Res. Treat.. 2017 Jan;161(1):73-81

Malignant Peripheral Nerve Sheath Tumor Is a Challenging Diagnosis: A Systematic Pathology Review, Immunohistochemistry, and Molecular Analysis in 160 Patients From the French Sarcoma Group Database.

Le Guellec S, Decouvelaere AV, Filleron T, Valo I, Charon-Barra C, Robin YM, Terrier P, Chevreau C, Coindre JM

Am. J. Surg. Pathol.. 2016 07;40(7):896-908

[An IgG4-related pancreatitis mimicking an adenocarcinoma: A case report].

Courcet E, Beltjens F, Charon-Barra C, Guy F, Orry D, Ghiringhelli F, Arnould L

Ann Pathol. 2015 Dec;35(6):511-4

HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable.

Beltjens F, Bertaut A, Pigeonnat S, Loustalot C, Desmoulins I, Charon-Barra C, Coudert B, Fumoleau P, Arveux P, Arnould L

Eur J Cancer Care (Engl). 2015 Oct 27

Acute and delayed toxicity of gemcitabine administered during isolated lung perfusion: a preclinical dose-escalation study in pigs.

Pagès PB, Derangere V, Bouchot O, Magnin G, Charon-Barra C, Lokiec F, Ghiringhelli F, Bernard A

Eur J Cardiothorac Surg. 2015 Aug;48(2):228-35

Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.

Guiu S, Charon-Barra C, Vernerey D, Fumoleau P, Campone M, Spielmann M, Roche H, Mesleard C, Arnould L, Lemonnier J, Lacroix-Triki M

Future Oncol. 2015 Aug;11(16):2283-97

Identification of biomarkers including 18FDG-PET/CT for early prediction of response to neoadjuvant chemotherapy in Triple Negative Breast Cancer.

Humbert O, Riedinger JM, Charon-Barra C, Berriolo-Riedinger A, Desmoulins I, Lorgis V, Kanoun S, Coutant C, Fumoleau P, Cochet A, Brunotte F

Clin Cancer Res. 2015 Jun 30. pii: clincanres.0384.2015.

Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.

Humbert O, Berriolo-Riedinger A, Cochet A, Gauthier M, Charon-Barra C, Guiu S, Desmoulins I, Toubeau M, Dygai-Cochet I, Coutant C, Fumoleau P, Brunotte F

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):416-27

Survivin-3B potentiates immune escape in cancer but also inhibits the toxicity of cancer chemotherapy.

Vegran F, Mary R, Gibeaud A, Mirjolet C, Collin B, Oudot A, Charon-Barra C, Arnould L, Lizard-Nacol S, Boidot R

Cancer Res. 2013 Sep 1;73(17):5391-401

Detection of plasma cells, C4d deposits and donor-specific antibodies on sequential graft biopsies of renal transplant recipients with chronic dysfunction.

Martin L, Charon-Barra C, Bocrie O, Guignier F, D'Athis P, Dautin G, de la Vega MF, Justrabo E, Rifle G, Mousson C

Transpl Immunol. 2010 Feb;22(3-4):110-4

Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.

Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J, Chapusot C, Piard F

Cancer Res.. 2008 Oct;68(20):8541-6

Recurrence of IgA nephropathy with crescents in kidney transplants.

Mousson C, Charon-Barra C, Funes de la Vega M, Tanter Y, Justrabo E, Martin L, Rifle G

Transplant Proc. 2007 Oct;39(8):2595-6.